What is Trastuzumab injection (subcutaneous injection) (Herceptin Hylecta)?

Trastuzumab injection (subcutaneous ) (Herceptin Hylecta) belongs to a class of drugs called monoclonal antibodies. It works by stopping the growth of cancer cells. Trastuzumab injection (subcutaneous injection) is supplied as a liquid and must be given by a doctor or nurse in a hospital or medical facility.

Trastuzumab injection (subcutaneous injection) can be used in the first-line treatment of HER2-overexpressing metastatic breast cancer (MBC) when combined with paclitaxel. It may also be used as a single agent to treat HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. Trastuzumab injection (subcutaneous injection) is suitable for adjuvant treatmentAdult patients with HER2-overexpressing lymph nodes that are positive or node-negative (ER/PR negative) or have a high-risk profile. paclitaxel or docetaxel); also as part of a docetaxel and carboplatin regimen; and as a single agent after multimodal anthracycline therapy.

It is understood that the original drug of trastuzumab injection (subcutaneous injection) has been launched in China, but the specific price and other relevant information are not yet clear. Since the drug has been on the market for a short time, it has not been included in the scope of medical insurance. At present, there are no generic drugs of Trastuzumab injection (subcutaneous injection) produced and marketed. For more information and specific prices of Trastuzumab injection (subcutaneous injection), please consult a medical consultant.